Serum Amyloid P-Component Prevents Cardiac Remodeling in Hypertensive Heart Disease

Area of Science:

• Cardiovascular Medicine
• Immunology
• Pharmacology

Background:

• Cardiac remodeling is a pathological process contributing to heart failure, particularly in hypertensive heart disease.
• Diastolic dysfunction (DD) is a key feature of hypertensive heart disease, often associated with cardiac fibrosis.
• Serum amyloid P-component (SAP) is a plasma protein with potential anti-inflammatory and anti-fibrotic properties.

Purpose of the Study:

• To investigate the potential of SAP to prevent cardiac remodeling in a model of hypertensive heart disease.
• To evaluate SAP's anti-fibrotic effects and its impact on macrophage infiltration in the heart.
• To assess SAP levels as a biomarker for identifying worsening diastolic dysfunction in patients.

Main Methods:

• An animal study using spontaneously hypertensive rats (SHRs) treated with SAP or vehicle for 12 weeks.
• Assessment of cardiac remodeling parameters including left ventricular mass, collagen deposition, and cardiomyocyte size.
• A prospective study of 60 patients with asymptomatic progressive diastolic dysfunction, analyzing SAP concentration over time.

Main Results:

• SAP treatment significantly reduced left ventricular mass, perivascular collagen, and cardiomyocyte size in SHRs compared to controls.
• SAP administration attenuated macrophage infiltration in the cardiac tissue of treated SHRs.
• Patients with progressive diastolic dysfunction showed a significant decrease in SAP concentration over time.

Conclusions:

• Serum amyloid P-component (SAP) demonstrates potential in preventing cardiac remodeling by inhibiting pro-fibrotic macrophage recruitment.
• Depleted SAP levels are associated with advancing diastolic dysfunction in patients, suggesting SAP's diagnostic and therapeutic relevance.
• SAP therapy may represent a novel approach for managing hypertensive heart disease and diastolic dysfunction.